Logo image of DMAA

DRUGS MADE IN AMERICA ACQUIS (DMAA) Stock Fundamental Analysis

NASDAQ:DMAA - Nasdaq - KYG2847J1040 - Common Stock - Currency: USD

10.11  0 (0%)

After market: 10.4 +0.29 (+2.87%)

Fundamental Rating

0

DMAA gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. Both the profitability and financial health of DMAA have multiple concerns. DMAA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

DMAA had negative earnings in the past year.
In the past year DMAA has reported a negative cash flow from operations.
DMAA Yearly Net Income VS EBIT VS OCF VS FCFDMAA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -50K -100K -150K -200K -250K

1.2 Ratios

Industry RankSector Rank
ROA -50.82%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DMAA Yearly ROA, ROE, ROICDMAA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 0 50 -50 100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DMAA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMAA Yearly Profit, Operating, Gross MarginsDMAA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, DMAA has less shares outstanding
DMAA Yearly Shares OutstandingDMAA Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 20M 40M 60M
DMAA Yearly Total Debt VS Total AssetsDMAA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 200K 400K 600K

2.2 Solvency

DMAA has an Altman-Z score of 251.43. This indicates that DMAA is financially healthy and has little risk of bankruptcy at the moment.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 251.43
ROIC/WACCN/A
WACCN/A
DMAA Yearly LT Debt VS Equity VS FCFDMAA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 -50K -100K -150K -200K

2.3 Liquidity

DMAA has a Current Ratio of 0.01. This is a bad value and indicates that DMAA is not financially healthy enough and could expect problems in meeting its short term obligations.
DMAA has a Quick Ratio of 0.01. This is a bad value and indicates that DMAA is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.01
Quick Ratio 0.01
DMAA Yearly Current Assets VS Current LiabilitesDMAA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2024 200K 400K 600K

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DMAA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMAA Price Earnings VS Forward Price EarningsDMAA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMAA Per share dataDMAA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0 -0 -0.01 -0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DMAA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DRUGS MADE IN AMERICA ACQUIS

NASDAQ:DMAA (5/12/2025, 4:30:01 PM)

After market: 10.4 +0.29 (+2.87%)

10.11

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)03-31 2025-03-31
Earnings (Next)N/A N/A
Inst Owners0.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap338.89M
AnalystsN/A
Price TargetN/A
Short Float %0.1%
Short Ratio0.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.01
Quick Ratio 0.01
Altman-Z 251.43
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A